$-1.88
(Market cap
$2,291 Mln
Revenue (TTM)
$189 Mln
P/E Ratio
--
P/B Ratio
19.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-14.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.6
-
Debt to Equity
-1.4
-
Book Value
$--
-
EPS
$-2
-
Face value
--
-
Shares outstanding
48,880,564
10 Years Aggregate
CFO
$-479.74 Mln
EBITDA
$-557.50 Mln
Net Profit
$-666.00 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
| 86.3 | 5.2 | 48.7 | 123.2 | 32.6 | 20.8 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
| 119.9 | 69.1 | -6.7 | -47.2 | -46.0 | -22.5 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
|
43.6 | 2,290.5 | 188.7 | -97.6 | -38.6 | -- | -- | 19.3 |
| 2.6 | 247.7 | 74.0 | 35.2 | 0.0 | 36.8 | 7.1 | 2.8 | |
| 0.5 | 8.9 | 1.3 | -9.1 | -1,029.8 | -- | -- | 6.2 | |
| 4.2 | 4.5 | 0.0 | -13.4 | -- | -90.4 | -- | 0.3 | |
| 68.8 | 254.1 | 1.8 | -16.3 | 0.0 | -46.1 | -- | 5.2 |
Shareholding Pattern
View DetailsAbout UroGen Pharma (URGN)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel... technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey. Read more
-
President, CEO & Director
Ms. Elizabeth A. Barrett
-
President, CEO & Director
Ms. Elizabeth A. Barrett
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for UroGen Pharma (URGN)
What is the current share price of UroGen Pharma Ltd (URGN) Today?
The share price of UroGen Pharma Ltd (URGN) is $43.62 (NASDAQ) as of 28-Aug-2026 16:00 EDT. UroGen Pharma Ltd (URGN) has given a return of 32.57% in the last 3 years.
What is the current PB & PE ratio of UroGen Pharma Ltd (URGN)?
Since, TTM earnings of UroGen Pharma Ltd (URGN) is negative, P/E ratio is not available.
The P/B ratio of UroGen Pharma Ltd (URGN) is 19.27 times as on 21-Aug-2026, a 579 premium to its peers’ median range of 2.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.51 |
-10.93 |
2024 |
-3.95 |
-56.90 |
2023 |
-5.30 |
-8.32 |
2022 |
-1.87 |
-2.29 |
2021 |
-1.93 |
25.36 |
What is the 52 Week High and Low of UroGen Pharma Ltd (URGN)?
The 52-week high and low of UroGen Pharma Ltd (URGN) are Rs 50.81 and Rs 15.86 as of 30-Aug-2026.
What is the market cap of UroGen Pharma Ltd (URGN)?
UroGen Pharma Ltd (URGN) has a market capitalisation of $ 2,291 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in UroGen Pharma Ltd (URGN)?
Before investing in UroGen Pharma Ltd (URGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.